Novo Nordisk
bd_ec70dd8f54a22f37 · schema v1 · pii pii-v1
Full breach record for Novo Nordisk →Threat-actor claim — not a regulatory filing
This row is a claim by the ransomware group Fulcrumsec on its public extortion blog. It has not been validated by the victim or any regulator. Treat attribution and counts as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Source: Ransomware.live
Post text · scraped from the leak site
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, it specializes in treatments for diabetes, obesity, hemophilia, and other chronic conditions. The company is a global leader in insulin production and develops drugs such as semaglutide. It operates in over 80 countries and is one of Europe's most valuable corporations by market capitalization.
Source provenance
- Source URL
- https://www.ransomware.live/id/Tm92byBOb3JkaXNrQGZ1bGNydW1zZWM=
DisclosureLens links to the originating regulator URL — full filing bodies are not redistributed from public surfaces (§4.5).
- Filed at
- Jun 16, 2026
- Raw hash
- a68bcccfdcf09a70bd576a42a4f6b8a39dde9f0d78ef92c5e9eeb9611b76d2f3
Reporting entity
- Name
- fulcrumsec
Victim entity
- Name
- Novo Nordisknorm: novo nordisk
- Industry
- Healthcarellm
What this source establishes
- Source ceiling
- A leak-site claim can't tell us: discovery date · materiality · notification · affected count · confirmed data types · compliance clock. These stay blank until a regulatory filing or victim disclosure lands.
- Attack vector
- Ransomware· fulcrumsec
- Threat actor
- FulcrumsecExternalFinancial
Compliance
- Compliance flags
- — (clock not assessable for this source)
Extraction provenance
- Status
- No extraction artifact recorded for this disclosure.